Last updated: 25 March 2024 at 9:48pm EST

Holdings A/S Novo Net Worth

The estimated Net Worth of Holdings A/S Novo is at least $350 Million dollars as of 21 March 2024. Holdings Novo owns over 465,021 units of Galecto stock worth over $33,456,000 and over the last 11 years Holdings sold GLTO stock worth over $316,438,455.

Holdings Novo GLTO stock SEC Form 4 insiders trading

Holdings has made over 60 trades of the Galecto stock since 2014, according to the Form 4 filled with the SEC. Most recently Holdings sold 465,021 units of GLTO stock worth $348,766 on 21 March 2024.

The largest trade Holdings's ever made was selling 3,610,487 units of Galecto stock on 14 December 2016 worth over $17,583,072. On average, Holdings trades about 625,876 units every 58 days since 2014. As of 21 March 2024 Holdings still owns at least 2,550,000 units of Galecto stock.

You can see the complete history of Holdings Novo stock trades at the bottom of the page.

What's Holdings Novo's mailing address?

Holdings's mailing address filed with the SEC is TUBORG HAVNEVEJ 19, , HELLERUP, G7, 2900.

Insiders trading at Galecto

Over the last 4 years, insiders at Galecto have traded over $2,298,261 worth of Galecto stock and bought 1,911,769 units worth $28,139,830 . The most active insiders traders include Holdings A/S Novo, Chau Quang Khuong, and Carl Goldfischer. On average, Galecto executives and independent directors trade stock every 46 days with the average trade being worth of $2,037,418. The most recent stock trade was executed by Advisors Llc Orbi Med Genes... on 15 August 2023, trading 822,680 units of GLTO stock currently worth $617,010.

What does Galecto do?

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Complete history of Holdings Novo stock trades at Akebia Therapeutics, AnaptysBio Inc, Apollo Endosurgery Inc, Corvus Pharmaceuticals Inc, Flexion Therapeutics Inc, HTG Molecular Diagnostics Inc, Inogen Inc, iRhythm Technologies Inc, KalVista Pharmaceuticals Inc, Otonomy Inc, Reata Pharmaceuticals Inc, Nevro Corp, Entasis Therapeutics Inc, Milestone Pharmaceuticals Inc, Morphic Inc, Mirum Pharmaceuticals Inc, Galera Therapeutics Inc, Nkarta, Inozyme Pharma, Checkmate Pharmaceuticals, Harmony Biosciences, Spruce Biosciences, Eargo, Praxis Precision Medicines, Aligos Therapeutics, and Galecto

Insider	Trans. Transaction	Total value
Holdings A/S Novo 10% owner	Sale	$348,766 21 Mar 2024
Holdings A/S Novo 10% owner	Sale	$1,364,199 18 Mar 2024
Holdings A/S Novo 10% owner	Sale	$1,701,961 14 Mar 2024
Holdings A/S Novo 10% owner	Buy	$6,999,360 16 Feb 2023
Holdings A/S Novo 10% owner	Sale	$6,602,500 19 May 2021
Holdings A/S Novo 10% owner	Buy	$3,750,000 14 Oct 2020
Holdings A/S Novo 10% owner	Sale	$23,032 23 Feb 2022
Holdings A/S Novo 10% owner	Buy	$7,500,000 11 Aug 2020
Holdings A/S Novo 10% owner	Sale	$38,977,600 2 Jun 2021
Holdings A/S Novo 10% owner	Sale	$38,710,000 1 Mar 2021
Holdings A/S Novo 10% owner	Sale	$43,000,000 4 Nov 2014
Holdings A/S Novo 10% owner	Sale	$9,180,960 20 Feb 2014
Holdings A/S Novo 10% owner	Sale	$5,290,000 18 Feb 2021
Holdings A/S Novo 10% owner	Sale	$4,950,000 15 Oct 2020
Holdings A/S Novo 10% owner	Buy	$6,000,000 12 Nov 2019
Holdings A/S Novo 10% owner	Buy	$4,999,995 2 Nov 2020
Holdings A/S Novo 10% owner	Buy	$3,000,000 20 Oct 2020
Holdings A/S Novo 10% owner	Buy	$2,700,000 20 Oct 2020
Holdings A/S Novo 10% owner	Buy	$3,180,072 21 Aug 2020
Holdings A/S Novo 10% owner	Buy	$6,000,000 28 Jul 2020
Holdings A/S Novo 10% owner	Buy	$9,999,990 14 Jul 2020
Holdings A/S Novo 10% owner	Sale	$8,167,109 7 Jul 2020
Holdings A/S Novo 10% owner	Sale	$6,076,331 23 Jul 2019
Holdings A/S Novo 10% owner	Buy	$9,999,995 12 Mar 2018
Holdings A/S Novo 10% owner	Buy	$219,000 23 Jun 2017
Holdings A/S Novo 10% owner	Buy	$700,000 12 May 2016
Holdings A/S Novo 10% owner	Buy	$9,999,990 29 Mar 2016
Holdings A/S Novo 10% owner	Sale	$3,840,000 25 Nov 2019
Holdings A/S Novo 10% owner	Option	$43,193,978 13 May 2019
Holdings A/S Novo 10% owner	Buy	$8,625,000 22 Jul 2019
Holdings A/S Novo 10% owner	Buy	$10,000,005 28 Jun 2019
Holdings A/S Novo 10% owner	Buy	$16,347,525 28 Sep 2018
Holdings A/S Novo 10% owner	Sale	$26,271,728 10 Oct 2017
Holdings A/S Novo 10% owner	Sale	$1,273,625 13 Sep 2017
Holdings A/S Novo 10% owner	Sale	$2,081,162 23 Aug 2017
Holdings A/S Novo 10% owner	Sale	$166,813 18 Aug 2017
Holdings A/S Novo 10% owner	Buy	$5,111,484 11 May 2015
Holdings A/S Novo 10% owner	Sale	$7,517,930 21 Aug 2017
Holdings A/S Novo 10% owner	Sale	$3,779,176 14 Aug 2017
Holdings A/S Novo 10% owner	Sale	$10,376,129 4 Aug 2017
Holdings A/S Novo 10% owner	Sale	$1,648,157 1 Aug 2017
Holdings A/S Novo 10% owner	Buy	$750,000 31 Jan 2017
Holdings A/S Novo 10% owner	Sale	$345,897 24 Jul 2017
Holdings A/S Novo 10% owner	Sale	$591,150 10 May 2017
Holdings A/S Novo 10% owner	Sale	$1,531,710 13 Jun 2017
Holdings A/S Novo 10% owner	Sale	$5,720,552 8 Jun 2017
Holdings A/S Novo 10% owner	Sale	$2,527,395 5 Jun 2017
Holdings A/S Novo 10% owner	Buy	$8,250,000 1 Jun 2016
Holdings A/S Novo 10% owner	Buy	$1,700,000 25 Oct 2016
Holdings A/S Novo 10% owner	Sale	$3,091,500 18 Jun 2015
Holdings A/S Novo 10% owner	Buy	$8,500,000 17 Dec 2014
Holdings A/S Novo 10% owner	Buy	$9,000,004 18 Feb 2014
Holdings A/S Novo 10% owner	Buy	$3,870,000 12 Nov 2014
Holdings A/S Novo 10% owner	Buy	$243,195 19 Aug 2014
Holdings A/S Novo 10% owner	Buy	$2,750,000 18 Aug 2014
Holdings A/S Novo 10% owner	Buy	$3,104,030 25 Mar 2014

Galecto executives and stock owners

Galecto executives and other stock owners filed with the SEC include:

Dr. Hans T. Schambye,
Co-Founder, Pres, CEO & Director
Prof. Bertil Lindmark M.D., Ph.D.,
Chief Medical Officer
Anders Pedersen,
Chief Operating Officer
Dr. Stephanie Oestreich Ph.D.,
Chief Bus. Officer
Garrett Winslow,
Sr. VP & Gen. Counsel
Jonathan P. Freve CPA, CPA,
Chief Financial Officer
Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP,
Co-Founder & Member of the Clinical Advisory Board - IPF
Dr. Hakon Leffler,
Co-Founder
Ulf J. Nilsson,
Co-Founder
Advisors Llc Orbi Med Genes...,
Holdings A/S Novo,
10% owner
Carl Goldfischer,
Anders Pedersen,
Chief Operating Officer
Hans T. Schambye,
Chief Executive Officer
Stephan Christgau,
Director
Advisors Llc Orbi Med Advis...,
Bertil Lindmark,
Chief Medical Officer
Jonathan Freve,
Chief Financial Officer
Chau Quang Khuong,
Director
Stephanie Oestreich,
Chief Business Officer
Jayson Donald Alexander Dallas,
Amit Munshi,
Anne Prener,
David Shapiro,
Garrett Winslow,
General Counsel